On October 14, 2026 Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, reported the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, Intermountain Health LDS Hospital, in Salt Lake City, Utah, is expected to begin screening and enrolling patients following completion of site initiation activities.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Intermountain Health LDS Hospital’s long-standing work in cellular therapy makes it a strong addition to STARLIGHT-1," said Cheng Liu, Ph.D., Chief Executive Officer of Estrella Immunopharma. "Each new site moves the dose-expansion phase forward and brings us closer to defining the path to a future pivotal study for EB103 in patients with R/R B-cell NHL."
The ongoing expansion phase of the Phase I/II clinical trial for EB103 is designed as a multi-center, open-label study intended to further evaluate the safety and efficacy of EB103 at the recommended Phase II dose (RP2D) in subjects (≥ 18 years of age) who have R/R B-cell NHL. Estrella expects that data from this expansion cohort will inform its pivotal trial strategy for EB103. As of the date of this press release, active clinical sites for the trial are UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, University Hospitals Cleveland Medical Center, and Intermountain Health LDS Hospital. Further details of the trial can be found at www.clinicaltrials.gov under NCT identifier NCT06343311.
About EB103
EB103, a T-cell therapy, also referred to as Estrella’s "CD19-Redirected ARTEMIS T-cell Therapy," utilizes ARTEMIS technology licensed from Eureka Therapeutics, Inc. (Eureka), Estrella’s parent company. Unlike a traditional CAR-T cell, the unique design of an ARTEMIS T-cell, such as EB103 allows it to be activated and regulated upon engagement with cancer targets through a cellular mechanism that more closely resembles that of an endogenous T-cell receptor. Once infused, EB103 T cells bind to and destroy CD19-positive cancer cells.
(Press release, Estrella Immunopharma, OCT 14, 2026, View Source [SID1234673469])